Among participants who met the core RESTORE-ALS Trial criteria (e.g., baseline serum NfL > 33 pg/mL, TRICALS risk score range between –6.5 and –2.5, baseline slow vital capacity > 60%, and symptom ...

AKGsOVIHAMS, a leading healthcare institution, has marked progress in treating ALS using integrative medicine. Known for combining conventional and alternative therapies, the institute has shown ...

A Regina mother who was one of the first ALS patients to test a new treatment is now celebrating its accelerated approval in ...

QurAlis Corporation ("QurAlis"), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of ...

Clene (CLNN) and its subsidiary, Clene Nanomedicine announced new evidence from a cross-regimen, post hoc analysis of long-term survival in ...

Denali Therapeutics’ amyotrophic lateral sclerosis (ALS) drug has racked up another clinical miss this year, leaving the ...

Pathmaker's MyoRegulator is designed to ease hyperexcitability and delivers an electrical current to the spinal cord and ...

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of eleven abstracts covering research in amyotrophic lateral sclerosis (ALS) at the 2025 Muscular Dystrophy Association ...

Find out about the new ALS blood test that offers accurate diagnosis and could replace traditional invasive testing methods.

Columnist Dagmar Munn says she has often felt out of place in the ALS community because of the slower pace of her disease progression.

ALS impacts tens of thousands of people across the United States, and hundreds in Arizona. There's research being done in the Valley that can hopefully help contribute to ending ALS.

Clene, Inc. (Nasdaq: CLNN) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment ...